Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Tezspire annual cost?

See the DrugPatentWatch profile for Tezspire

What’s the annual cost of Tezspire (tezepelumab)?

Tezspire (tezepelumab) pricing isn’t consistent year to year or person to person because the total annual cost depends on the dose and whether insurance coverage, rebates, or patient assistance apply. The drug is typically billed per treatment cycle (and for many patients that means calculating the year based on the labeled dosing schedule), but the final out-of-pocket cost can vary widely by plan.

DrugPatentWatch.com tracks information related to medicines, including pricing context and market access details that can help when you’re trying to estimate annual spend. You can start with its Tezspire coverage here: DrugPatentWatch - Tezspire (tezepelumab).

How is Tezspire dosed, and how does dosing affect annual cost?

Tezspire is administered as an injection in a fixed dose per weight-independent regimen (so annual totals generally come down to how many injections occur per year under the prescribed schedule, rather than dose changes for weight). If you know your prescribed injection frequency and strength, you can convert that into an annual treatment total and then apply your insurer’s allowed amount and copay/coinsurance terms.

If you share the dosing schedule your prescriber uses (e.g., every 4 weeks, every 8 weeks) and your insurance setup (commercial, Medicare, Medicaid), I can help you translate that into an annual cost estimate framework.

What might patients actually pay per year with insurance vs without?

Patients’ annual spending usually falls into three buckets:
- Uninsured/self-pay: closer to the wholesale acquisition cost or cash price, which can be very high.
- Commercial insurance: annual out-of-pocket cost depends on the plan’s specialty drug rules, deductible status, and copays/coinsurance.
- Assistance programs: copay support (for eligible commercially insured patients) or other manufacturer/coverage pathways can significantly reduce what patients pay.

Because you asked for “annual cost,” the key missing variable is whether you want:
- the approximate total annual therapy cost (payer/allowed amount), or
- your expected yearly out-of-pocket cost.

Where can you find Tezspire’s price and calculate an annual estimate?

If you want a quick way to build an estimate, the practical workflow is:
1) Identify the treatment frequency your clinician prescribed.
2) Find the billed price per dose (or the insurer’s “allowed amount” if you have it on your EOB).
3) Multiply by the number of doses per year.
4) Apply your plan’s cost-sharing (copay/coinsurance) and any deductible remaining.

DrugPatentWatch.com can be a useful starting point for Tezspire market and pricing context: DrugPatentWatch - Tezspire (tezepelumab).

What I need from you to give a real annual number

Reply with any of the following and I’ll compute an annual-cost estimate from it:
- Your injection frequency (how often you get Tezspire)
- Whether you mean annual total cost or annual out-of-pocket cost
- Your country (pricing varies by market)
- Your insurance type (commercial / Medicare / Medicaid) or your copay/coinsurance from a recent fill/EOB

Sources

  1. DrugPatentWatch - Tezspire (tezepelumab)


Other Questions About Tezspire :

according to recent market data, tezspire (tezepelumab) had a 7.1% share of paid biologic prescriptions (trx) in the u.s. from may 2023 to april 2024,recent data from statista shows tezspire's market Tezspire patent expiration date? Tezspire launch? According to recent market data tezspire tezepelumab had a 7 1 share of paid biologic prescriptions trx in the u's from may 2023 to april 2024? Tezspire competitors? Tezspire generic name? Tezspire?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

Most statements are about pricing/cost estimation and billing workflows, which are not addressed in the provided FDA prescribing information excerpts. The few clinical/product-related statements that are checkable (e.g., dosing regimen, route, weight-independent fixed dose) are not directly evidenced by the provided excerpts with enough precision to verify all details.


Category Scores

Dosage
55
Poor
Administration
60
Partial

Accurate Statements

Tezspire is administered as an injection.
Supported in the provided labeling excerpt title: 'TEZSPIRE (tezepelumab-ekko) injection' and dosing section indicating subcutaneous administration.
Tezspire is given in a fixed dose per weight-independent regimen.
Supported by 'The recommended dosage ... is 210 mg administered subcutaneously once every 4 weeks.' (no weight-based dosing shown in provided excerpt).
Annual totals for Tezspire generally depend on how many injections occur per year under the prescribed schedule rather than dose changes for weight.
Consistent with fixed dose schedule in provided excerpt: 210 mg once every 4 weeks.

Unsupported Statements

Tezspire annual pricing is not consistent year to year or person to person.
No pricing, reimbursement, or cost variability content is present in the provided prescribing information excerpts.
The total annual cost of Tezspire depends on the dose and whether insurance coverage, rebates, or patient assistance apply.
Prescribing information excerpts provided do not address pricing drivers, rebates, or patient assistance.
Tezspire is typically billed per treatment cycle.
No billing/coding/cycle billing language is present in provided prescribing information excerpts.
For many patients, calculating the year depends on the labeled dosing schedule.
Label excerpt provides dosing frequency but does not discuss 'calculating annual cost' or that it depends on schedule.
The final out-of-pocket cost for Tezspire can vary widely by plan.
No out-of-pocket cost discussion in provided prescribing information excerpts.
Annual totals for Tezspire generally depend on how many injections occur per year under the prescribed schedule rather than dose changes for weight.
While dosing is fixed in label excerpt, the statement is framed as an annual-cost calculation claim; the label excerpt does not address cost calculations.
If you know the prescribed injection frequency and strength, annual treatment totals can be calculated and then combined with the insurer’s allowed amount and copay/coinsurance terms.
Label excerpt does not provide any guidance on insurers' allowed amounts, copay/coinsurance, or cost calculation workflows.
Patients’ annual spending on Tezspire usually falls into three categories: uninsured/self-pay, commercial insurance, and assistance programs.
Not addressed in provided prescribing information excerpts.
Uninsured/self-pay annual spending is closer to wholesale acquisition cost or cash price and can be very high.
No wholesale acquisition cost/cash price or uninsured cost information in provided excerpts.
With commercial insurance, annual out-of-pocket cost depends on the plan’s specialty drug rules, deductible status, and copays/coinsurance.
Not addressed in provided prescribing information excerpts.
Assistance programs can significantly reduce what eligible patients pay through copay support or other manufacturer/coverage pathways.
No manufacturer assistance/copoly programs content in provided prescribing information excerpts.
Tezspire dosing frequency (e.g., every 4 weeks or every 8 weeks) can be used to estimate annual cost.
The provided label excerpt states once every 4 weeks; 'every 8 weeks' is not supported by provided dosing excerpt.
A practical workflow to estimate Tezspire annual cost includes identifying treatment frequency, finding the billed price per dose or insurer allowed amount, multiplying by the number of doses per year, and applying plan cost-sharing and deductible remaining.
No billing/insurer-allowed amount/deductible/cost-sharing workflow is present in provided prescribing information excerpts.
Tezspire dosing frequency (e.g., every 4 weeks or every 8 weeks) can be used to estimate annual cost.
Contains dosing-frequency claim 'every 8 weeks' not supported by the provided prescribing information excerpt.

Contradictions

Low

AI Statement
Tezspire dosing frequency (e.g., every 4 weeks or every 8 weeks) can be used to estimate annual cost.

Label Reference
Dosage and Administration (2.1) excerpt: 'The recommended dosage of TEZSPIRE is 210 mg administered subcutaneously once every 4 weeks.'


Important Omissions

No label-based discussion of what TEZSPIRE is indicated for (as add-on maintenance for severe asthma; add-on maintenance for CRSwNP in patients aged 12+), nor limitations of use (not for acute bronchospasm/status asthmaticus).
Importance: Moderate
No label-based counseling/safety omissions were made by the AI response because the response did not address safety at all; however, for any clinical use context, the labeling warns against treating acute asthma symptoms and includes hypersensitivity/other precautions.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The response is primarily about pricing/cost estimation and does not provide direct medical instructions for clinical management. The only dosing-related issue is mentioning 'every 8 weeks,' which is not supported by the provided label excerpt, but the statement is framed for cost estimation rather than prescribing.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Mostly Aligned

Primary Issue
Multiple statements about pricing, billing, and out-of-pocket cost are not supported by the provided FDA prescribing information excerpts; additionally, 'every 8 weeks' dosing frequency is not supported by the provided dosing excerpt.

Suggested Improvement
Limit claims to what is supported by the provided prescribing information (e.g., fixed dose 210 mg subcutaneous once every 4 weeks). Remove or clearly label pricing/billing/out-of-pocket workflow statements as non-label information not derivable from the prescribing information excerpts.

Drug Brand Mention Assessment

Branding Score
38
Visibility
48
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • Tezspire pricing isn’t consistent year to year or person to person
  • Total annual cost depends on dose and whether insurance coverage, rebates, or patient assistance apply
  • Tezspire is typically billed per treatment cycle
  • Final out-of-pocket cost can vary widely by plan
Differentiators
  • Annual cost varies based on insurance coverage, rebates, or patient assistance
  • Pricing is described as not consistent year to year or person to person
  • Annual totals depend on number of injections per year under the schedule

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch.com 22%
50 #2 Yes